Ovarian neuroendocrine neoplasm

Summary

Ovarian neuroendocrine neoplasm (MONDO:0002481) is a cancer and 1 clinical trial. Top therapeutic interventions include lutetium lu177 edotreotide. A subtype of ovarian cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian neuroendocrine neoplasm
Mondo ID	MONDO:0002481
DOID	DOID:3002
NCIT	C5237
UMLS	C1335172
MedGen	277459
GARD	0023145
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	yes

Also known as: neuroendocrine neoplasm of ovary · neuroendocrine neoplasm of the ovary · neuroendocrine tumour of ovary · ovarian neuroendocrine neoplasm · ovary NET · ovary neuroendocrine neoplasm · ovary neuroendocrine tumor · ovary neuroendocrine tumor, well differentiated, low or intermediate grade · ovary neuroendocrine tumour

Disease family

This is a subtype of ovarian cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › ovarian cancer › ovarian neuroendocrine neoplasm

Related subtypes (10): ovarian malignant mesothelioma, malignant ovarian cyst, ovarian sarcoma, ovarian lymphoma, ovarian Wilms tumor, ovarian adenosarcoma, ovarian endometrioid adenocarcinofibroma, familial ovarian cancer, malignant epithelial tumor of ovary, malignant non-epithelial tumor of ovary

Subtypes (2): ovarian large-cell neuroendocrine carcinoma, ovarian small cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04276597	PHASE2	WITHDRAWN	Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LUTETIUM LU177 EDOTREOTIDE	2	1